Tue 5/21/2013 18:47 ET
DJIA15387.5852.320.34%SOLAR25.840.301.17%GOLD1373.9010.200.74%Shanghai2305.115.070.22%
S&P 5001669.162.840.17%BANKS20.040.050.25%OIL96.020.910.94%Nikkei15381.0220.000.13%
NASDAQ3502.125.600.16%SEMI38.560.090.23%US/EU0.770.000.20%Futures1665.900.300.02%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Cyclacel Pharmaceuticals - CYCC   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CYCC
  
From: giggy (Rep: 15) reply to SpecGuruDate: 03/29/2012 10:45
Forum: Cyclacel Pharmaceuticals - Msg #3143Thread #673380476 (Rec: 0)
I am buying in every penny drop. Re: Grab some. New data presents. AACR 103rd Annual Meeting -- Saturday, March 3...

Share This Post:




Reply to SpecGuru - Msg #2253466 - 03/29/2012 10:38

Grab some. New data presents. AACR 103rd Annual Meeting -- Saturday, March 31 to Wednesday, April 4, 2012 26-Mar-12 04:38 pm


American Association for Cancer Research (AACR) 103rd Annual Meeting -- Saturday, March 31 to Wednesday, April 4, 2012

Three abstracts discussing translational research findings on Cyclacel's sapacitabine, currently in a Phase 3 clinical study, and two abstracts discussing Cyclacel's selective PLK1 and Aurora A inhibitors, currently in preclinical development, have been selected for presentation at the AACR 103rd Annual Meeting in Chicago, IL.

The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of presentation.

Sapacitabine:



"DNA repair defects enhance tumor cell sensitivity to sapacitabine"



Date/Time: Wednesday, April 4, 2012, 8:00 AM -- 12:00 PM CDT



Abstract Number: 5666





"Mechanism-based combinations of agents impacting the homologous recombination and nucleotide excision repair pathways"*



Date/Time: Wednesday, April 4, 2012, 8:00 AM -- 12:00 PM CDT



Abstract Number: 5667





"Patient AML cells and AML cell lines are highly sensitive to CNDAC, the active form of sapacitabine"*



Date/Time: Tuesday, April 3, 2012, 1:00 PM -- 5:00 PM CDT



Abstract Number: 4668





Polo-like kinase 1 (Plk1):



"Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization"



Date/Time: Monday, April 2, 2012, 1:00 PM -- 5:00 PM CDT



Abstract Number: 2814




Aurora Kinase A:



"The aurora kinase inhibitor CYC3 synergizes with low concentrations of paclitaxel in pancreatic cancer cells in vitro"



Date/Time: Monday, April 2, 2012, 8:00 AM -- 12:00 PM CDT



Abstract Number: 1924
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser giggy: Reward | Watch | IgnoreCYCC: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CYCC
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.